GNMSF News Alert Genmab A/S Dkk (GNMSF) 57.6000 12/25/2014 0

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Genmab A/S Dkk (GNMSF) 57.6000 $GNMSF

How Genmab (GNMSF) Stock Stands Out in a Strong Industry - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 19, 7:30AM CST
Genmab is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.

Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/dsgsvz/chronic) has announced the addition of the "Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Amgen Inc. - Sanofi - Eli Lilly and Company - Viralytics Ltd. - Genentech, Inc. - MedImmune, LLC - Gilead Sciences, Inc. - Daiichi Sankyo Company, Limited - Emergent BioSolutions Inc. - Lentigen Corporation - Amorfix Life Sciences Ltd. - Piramal Enterprises Limited - Celltrion, Inc. - Astellas Pharma Inc. - BioMarin Pharmaceutical Inc. - Richter Gedeon Nyrt. - Astex Pharmaceuticals, Inc. - Genmab A/S - Cyclacel Pharmaceuticals Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Bayer AG - Incyte Corporation - Merck KGaA - 4SC AG - Celldex Therapeutics, Inc. - Immunomedics, Inc. - TG Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/dsgsvz/chronic
BMRN: 88.18 (+0.89), CLDX: 17.08 (-0.18), CYCC: 0.69 (+0.01), IMMU: 4.41 (+0.13), EBS: 27.64 (+1.28), INCY: 71.57 (+1.99), TGTX: 16.03 (+0.33), AMGN: 160.67 (+3.15), LLY: 70.16 (+0.42), BMY: 59.15 (-0.01), GILD: 91.29 (+1.84), CELGZ: 3.34 (-0.01)

Genmab to Receive $3 Million Milestone Payment in DuoBody Platform Collaboration with Janssen
GlobeNewswire - Fri Dec 12, 12:59PM CST
Genmab A/S (Copenhagen:GEN) announced today it has reached a milestone in its DuoBody technology platform collaboration with Janssen Biotech, Inc. ("Janssen" , triggering a $3 million payment. The milestone payment is for pre-clinical progress with a DuoBody product candidate targeting cancer.

Amgen Hopes Sentiment Swings Sweeter for Myeloma Drug at Key Blood Cancer Meeting
at The Street - Sat Dec 06, 10:00AM CST
Scientists and investors are getting their first detailed look this weekend at a large study of Amgen's multiple myeloma drug Kyprolis.
AMGN: 160.67 (+3.15), SNY: 46.35 (+0.50), CELG: 109.60 (+3.48)

Genmab Announces Phase II Study of Daratumumab in Non-Hodgkin's Lymphomas
GlobeNewswire - Thu Dec 04, 12:36AM CST
Company Announcement

Genmab Announces Phase II Study of Daratumumab in Smoldering Multiple Myeloma
GlobeNewswire - Mon Nov 24, 7:53AM CST
Company Announcement

Global Cervical Cancer Therapeutic Pipeline Review, H2 2014 - 35 Companies & 71 Drug Profiles
M2 - Wed Nov 19, 4:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/4p52hn/cervical_cancer) has announced the addition of the "Cervical Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cervical Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cervical Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Sanofi - GlaxoSmithKline plc - Nektar Therapeutics - Inovio Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Amorfix Life Sciences Ltd. - MediGene AG - Nanotherapeutics, Inc. - Arbor Vita Corporation - Novartis AG - Chong Kun Dang Pharmaceutical Corp. - Taiho Pharmaceutical Co., Ltd. - Zeria Pharmaceutical Co Ltd - Genmab A/S - Advaxis, Inc. - 3SBio Inc. - Transgene SA - Antigen Express, Inc. - Shantha Biotechnics Limited - Bionor Pharma ASA - Azaya Therapeutics Incorporated - Merrimack Pharmaceuticals, Inc. - Genexine, Inc. - Genticel - Sirnaomics, Inc. - EyeGene, Inc. - Vaccibody AS - Wellstat Biologics Corporation - ISA Pharmaceuticals B.V. For more information visit http://www.researchandmarkets.com/research/4p...cal_cancer
MACK: 10.91 (+0.36), INO: 9.11 (-0.09), ADXS: 7.57 (+0.50), GSK: 42.85 (+0.11), NKTR: 15.02 (+0.23), NVS: 93.91 (+0.66)

Genmab's (GNMSF) CEO Jan Winkel on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 11, 1:16AM CST


Genmab Announces New Phase III Combination Study of Daratumumab in Frontline Multiple Myeloma
GlobeNewswire - Mon Nov 10, 2:17AM CST
Company Announcement

Genmab Announces Daratumumab and Ofatumumab Data to Be Presented at American Society of Hematology Annual Meeting (ASH)
GlobeNewswire - Thu Nov 06, 8:46AM CST
Media Release

Genmab Announces Additional Data from Phase III Study of Ofatumumab as Maintenance Therapy for Relapsed CLL
GlobeNewswire - Thu Nov 06, 8:46AM CST
-- 13.4 month improvement in median progression free survival in patients receiving ofatumumab maintenance therapy for relapsed CLL

Genmab Announces Financial Results for the First Nine Months of 2014
GlobeNewswire - Wed Nov 05, 10:24AM CST
Interim Report for the Nine Months Ended September 30, 2014

Genmab Announces Conditional Transfer of Ofatumumab Agreement
GlobeNewswire - Mon Nov 03, 12:26AM CST
Company Announcement
NVS: 93.91 (+0.66)

Genmab Reaches USD 10 Million Milestone in Daratumumab Collaboration with Janssen
GlobeNewswire - Thu Oct 23, 11:52AM CDT
Company Announcement

Third Quarter 2014 Net Sales Figures for Arzerra(r)
GlobeNewswire - Wed Oct 22, 6:05AM CDT
Company Announcement

OMT Grants Unlimited OmniRat, OmniMouse and OmniFlic License
Business Wire - Wed Oct 01, 10:22AM CDT
Open Monoclonal Technology, Inc. (OMT), an innovator of novel genetic engineering of animals for creation of human therapeutic antibodies, today announced an alliance with Genmab A/S (OMX: GEN), a biotechnology company specializing in human antibody therapeutics. The deal gives Genmab unlimited access to OMT's three OmniAb(TM) platforms, OmniRat(R), OmniMouse(R) and OmniFlic(TM).

Seattle Genetics and Genmab Enter Into New Antibody-Drug Conjugate Collaboration
GlobeNewswire - Wed Sep 10, 7:15AM CDT
Company Announcement
SGEN: 31.10 (-0.14)

Major Shareholder Announcement
GlobeNewswire - Mon Aug 25, 11:08AM CDT
Company Announcement

Genmab Announces Financial Results for the First Half of 2014 and Improves 2014 Financial Guidance
GlobeNewswire - Wed Aug 13, 10:10AM CDT
Interim Report First Half 2014

Genmab Announces New Phase III Study of Daratumumab in Front Line Multiple Myeloma
GlobeNewswire - Mon Aug 11, 9:00AM CDT
Company Announcement




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sports Leagues Confront Youth Gambling's Hard Truth

Updated Category News Views 70

A stadium-sized advertising machine cannot pretend kids are not watching. That is the uncomfortable backdrop to the National Council on Problem Gambling's November 10 youth gambling prevention summit, where representatives from the NFL, MLB, NBA and PGA Tour met at the NFL's New York offices. Good that they showed up. Frankly, with gambling stitched into so much sports...

Continue Reading
Pinnacol’s Community Work Earns Denver Chamber Recognition

Updated Category News Views 67

A workers’ comp insurer usually becomes visible on somebody’s worst day; Pinnacol Assurance is being recognized for the work it keeps doing around those days. The Denver Metro Chamber of Commerce has given the Colorado-based, member-owned carrier its 2026 Business Impact Award for Corporate Social Responsibility. Awards can be cheap applause, frankly. This one...

Continue Reading
Water Damage Coverage Has More Traps Than Homeowners Think

Updated Category News Views 36

A wet basement does not care one bit whether the water arrived dramatically or dripped in for months. That ugly distinction, though, can decide whether a homeowner has an insurance claim or a repair bill that lands with a thud. Kathy Thurmond-Edwards, an insurance expert in Memphis, Tennessee, lays out the dividing lines plainly: sudden pipe failures may be treated very...

Continue Reading
COFE+ Barista Test Puts Robotic Coffee on the Clock

Updated Category News Views 84

A swan latte taking 18 seconds less is not nothing, even if it is hardly a verdict on the future of coffee. COFE+, the seventh-generation robotic barista from Shanghai Hi-Dolphin Robot Technology, beat an award-winning human barista across five drinks at a live November 14 competition in Yiwu. That is a clean, visible demonstration of what machines are increasingly built...

Continue Reading
Trump's Reagan Forum Speech Puts Defense in Focus Again

Updated Category News Views 118

A December podium in Simi Valley has suddenly become a market-relevant appointment. The Ronald Reagan Presidential Foundation and Institute says President Donald J. Trump will deliver the keynote at the 2026 Reagan National Defense Forum on Friday, December 4, at 3:00 p.m. Pacific time, or 6:00 p.m. Eastern. That is the whole hard fact pattern so far. No agenda, no...

Continue Reading
CASEKOO's Montana Story Makes Brand Purpose Personal

Updated Category News Views 45

A blurry Montana kitchen, not a glossy product render, is doing the heavy lifting for CASEKOO this Thanksgiving. That is either a smart bit of brand discipline or a sentimental detour, depending on whether the company can make people feel something without losing sight of why they bought a phone case in the first place. Warmth Takes the Place of Hardware CASEKOO's new...

Continue Reading
North Richland Hills Bets on Its Visitor Momentum Now

Updated Category News Views 65

A crowded family attraction map is a nice problem for a Texas city to have, and North Richland Hills is trying to turn that pile of assets into a cleaner regional tourism machine. On Nov. 20, 2026, the city introduced “The Place You Never Outgrow,” its first destination-marketing campaign, built with Flat Five Marketing. This is not a stock story in the usual...

Continue Reading
California Stone Ban Puts a Hidden Worker Toll in View

Updated Category News Views 42

Countertops are supposed to finish a kitchen, not quietly wreck the lungs of the people cutting them. Yet California's move toward prohibiting the fabrication and installation of artificial stone containing more than 1% crystalline silica puts an ugly, long-running occupational-health problem in plain sight. This is not a story that calls for chest-thumping market talk....

Continue Reading
U.S. Employers Signal a Deeper Multilingual Skills Gap

Updated Category News Views 125

A language gap rarely makes the loudest noise in an earnings call, yet it can quietly wreck a sales effort, a hiring plan, or a customer relationship. ACTFL's updated 2026 employer study puts some hard edges around that problem: U.S. businesses say multilingual capability is not a nice cultural accessory. It is increasingly part of operating the business. Demand Has Moved...

Continue Reading
Arizona's Dry Climate Puts Scalp Health Under Stress

Updated Category News Views 77

Desert weather is unforgiving, and apparently the scalp does not get a pass. In a Nov. 20, 2026 discussion, Scottsdale and Tucson hair-restoration physician Dr. Sharon A. Keene frames Arizona hair concerns around something easy to overlook: the condition of the skin beneath the hair. That is a more sensible starting point than treating every strand in the shower like it...

Continue Reading

Top 5 Most Recently Viewed Articles

Music City San Francisco: A New Chapter for Local Artists

Updated Category News Views 307

Exciting Grand Opening of Music City San Francisco Rudy Colombini, a well-known figure in the local music scene, is making waves with his ambitious project, Music City San Francisco. This unique venue spans an impressive 29,000 square feet and is designed to rejuvenate San Francisco's status as a vibrant musical hub. Festival Kicks Off at the Grand Opening The festivities...

Continue Reading
Amplify Classroom Revolutionizes K-12 Teaching Experience

Updated Category News Views 890

Amplify Unveils Innovative Teaching Platform for Educators Amplify has introduced its latest initiative, Amplify Classroom, aimed at enhancing the educational experience for teachers and students alike. This platform is designed to provide educators with a comprehensive suite of tools and resources to support interactive and impactful teaching. A Large Library of Free...

Continue Reading
Countries Leading the Global Economy in 2026

Updated Category Economy Views 228

The world's economic map is not static. Rankings shift as countries grow, stumble, or restructure, and the metrics used to measure strength produce very different pictures depending on what you prioritize. Nominal GDP, purchasing power parity, GDP per capita, and innovation indices each tell a different part of the story. For a trader or investor, understanding which...

Continue Reading
RYVYL's Strategic Move in Pre-funded Asset Sale Negotiation

Updated Category News Views 272

RYVYL Inc. Ends Negotiations on Asset Sale Restructuring - Buyer intends to close the pre-funded asset sale - RYVYL Inc. (NASDAQ: RVYL), renowned for its innovative payment transaction solutions, has recently made a significant strategic decision concerning its RYVYL EU subsidiary. The company has ceased all discussions regarding the restructuring of the pre-funded asset...

Continue Reading
Investors Urged to Join James Hardie Class Action Lawsuit

Updated Category News Views 152

Class Action Lawsuit Against James Hardie Industries plc In a significant legal move, a class action lawsuit has been initiated against James Hardie Industries plc (NYSE: JHX). The lawsuit brings attention to concerns over potential inaccuracies in the company’s financial disclosures. The law firm Robbins Geller Rudman & Dowd LLP is leading the charge, encouraging...

Continue Reading